JP7105797B2 - 化合物及びその使用方法 - Google Patents

化合物及びその使用方法 Download PDF

Info

Publication number
JP7105797B2
JP7105797B2 JP2019548536A JP2019548536A JP7105797B2 JP 7105797 B2 JP7105797 B2 JP 7105797B2 JP 2019548536 A JP2019548536 A JP 2019548536A JP 2019548536 A JP2019548536 A JP 2019548536A JP 7105797 B2 JP7105797 B2 JP 7105797B2
Authority
JP
Japan
Prior art keywords
alkyl
carbocyclyl
optionally substituted
cyano
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535838A (ja
JP2019535838A5 (https=
Inventor
キラン レディ，
ボテッラ， ガブリエル マルティネス
アンドリュー マーク グリフィン，
ブライアン エドワード マロン，
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2019535838A publication Critical patent/JP2019535838A/ja
Publication of JP2019535838A5 publication Critical patent/JP2019535838A5/ja
Priority to JP2022111844A priority Critical patent/JP7495962B2/ja
Application granted granted Critical
Publication of JP7105797B2 publication Critical patent/JP7105797B2/ja
Priority to JP2024084718A priority patent/JP7801794B2/ja
Priority to JP2025279047A priority patent/JP2026062794A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019548536A 2016-11-28 2017-11-28 化合物及びその使用方法 Active JP7105797B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022111844A JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A JP7801794B2 (ja) 2016-11-28 2024-05-24 化合物及びその使用方法
JP2025279047A JP2026062794A (ja) 2016-11-28 2025-12-23 化合物及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662427044P 2016-11-28 2016-11-28
US62/427,044 2016-11-28
US201762458306P 2017-02-13 2017-02-13
US62/458,306 2017-02-13
US201762552073P 2017-08-30 2017-08-30
US62/552,073 2017-08-30
PCT/US2017/063533 WO2018098499A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022111844A Division JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019535838A JP2019535838A (ja) 2019-12-12
JP2019535838A5 JP2019535838A5 (https=) 2021-01-07
JP7105797B2 true JP7105797B2 (ja) 2022-07-25

Family

ID=62195384

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019548536A Active JP7105797B2 (ja) 2016-11-28 2017-11-28 化合物及びその使用方法
JP2022111844A Active JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A Active JP7801794B2 (ja) 2016-11-28 2024-05-24 化合物及びその使用方法
JP2025279047A Pending JP2026062794A (ja) 2016-11-28 2025-12-23 化合物及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022111844A Active JP7495962B2 (ja) 2016-11-28 2022-07-12 化合物及びその使用方法
JP2024084718A Active JP7801794B2 (ja) 2016-11-28 2024-05-24 化合物及びその使用方法
JP2025279047A Pending JP2026062794A (ja) 2016-11-28 2025-12-23 化合物及びその使用方法

Country Status (14)

Country Link
US (3) US11629146B2 (https=)
EP (2) EP3548033B1 (https=)
JP (4) JP7105797B2 (https=)
CN (2) CN116763791A (https=)
AU (3) AU2017364901A1 (https=)
BR (1) BR112019010880A2 (https=)
CA (2) CA3281817A1 (https=)
DK (1) DK3548033T3 (https=)
ES (1) ES2992063T3 (https=)
FI (1) FI3548033T3 (https=)
HU (1) HUE068842T2 (https=)
PL (1) PL3548033T3 (https=)
PT (1) PT3548033T (https=)
WO (1) WO2018098499A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525800A (ja) * 2018-05-30 2021-09-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
BR112021003224A2 (pt) 2018-08-20 2021-07-20 Rogcon, Inc. oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a
EA202092908A1 (ru) * 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
WO2021039961A1 (ja) * 2019-08-30 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体
CN114980899A (zh) * 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) * 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
JP2021195367A (ja) * 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
PE20242111A1 (es) 2021-09-13 2024-10-28 Boehringer Ingelheim Vetmedica Gmbh Derivados de etilsulfonil-piridina sustituidos con ciclopropil-(hetero)arilo
KR20250005348A (ko) * 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료
CN120641418A (zh) * 2022-10-07 2025-09-12 腾维治疗公司 化合物、组合物和方法
WO2026082004A1 (zh) * 2024-10-14 2026-04-23 上海京新生物医药有限公司 稠合杂芳基衍生物及其制备方法与应用
CN119613413B (zh) * 2024-12-26 2026-02-06 上海皓元医药股份有限公司 一种非唑奈坦的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021521A1 (en) 2009-07-27 2011-01-27 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1080712A (en) 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
WO2002006286A2 (en) 2000-07-14 2002-01-24 Bristol-Myers Squibb Pharma Company IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
SI1644019T2 (en) * 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
AU2005212096B2 (en) * 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
CA2713521A1 (en) 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
MX342128B (es) 2008-12-24 2016-09-14 Bial - Portela & C A S A Compuestos farmaceuticos.
JP5340798B2 (ja) 2009-05-07 2013-11-13 タイガースポリマー株式会社 地中埋設管の製造方法
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2012151136A1 (en) 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
NO3175985T3 (https=) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2013045519A1 (en) 2011-09-27 2013-04-04 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
WO2014179492A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
DK3035926T3 (da) 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
NZ720651A (en) 2013-12-19 2017-12-22 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
TW201609741A (zh) * 2014-06-04 2016-03-16 盧郡控股（開曼）有限公司 作為ｎｒ２ｂ ｎｍｄａ受體拮抗劑之二氟乙基吡啶衍生物
ES2912073T3 (es) 2014-06-20 2022-05-24 Mitsubishi Chem Corp Policarbonatodiol, método para producir el mismo, y poliuretano producido usando el mismo
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2015279377B2 (en) 2014-06-26 2019-09-12 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
DK3548033T3 (da) 2016-11-28 2024-07-15 Praxis Prec Medicines Inc Forbindelser og deres fremgangsmåde til anvendelse
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098500A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
MX2020012838A (es) 2018-05-30 2021-07-16 Praxis Prec Medicines Inc Moduladores de los canales ionicos.
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
CN114980899A (zh) 2019-11-26 2022-08-30 普拉西斯精密医药公司 离子通道调节剂
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021521A1 (en) 2009-07-27 2011-01-27 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
European Journal of Medicinal Chemistry，2010年，45，pp.1746-1752
FILE REGISTRY ON STN, RN 1347643-11-1, Entered STN: 02 Dec 2011
J. Med. Chem.，1981年，24，pp.592-600

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021525800A (ja) * 2018-05-30 2021-09-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP2023144130A (ja) * 2018-05-30 2023-10-06 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP7359847B2 (ja) 2018-05-30 2023-10-11 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
JP7603118B2 (ja) 2018-05-30 2024-12-19 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター

Also Published As

Publication number Publication date
CN116763791A (zh) 2023-09-19
WO2018098499A1 (en) 2018-05-31
US20230322790A1 (en) 2023-10-12
EP3548033A1 (en) 2019-10-09
JP2019535838A (ja) 2019-12-12
CA3045121A1 (en) 2018-05-31
FI3548033T3 (fi) 2024-07-10
PL3548033T3 (pl) 2025-06-02
JP7801794B2 (ja) 2026-01-19
AU2025237912A1 (en) 2025-10-16
US20210188852A1 (en) 2021-06-24
EP4397308A2 (en) 2024-07-10
EP3548033B1 (en) 2024-04-10
EP3548033A4 (en) 2020-09-09
CN110337295B (zh) 2023-06-09
JP2024100974A (ja) 2024-07-26
BR112019010880A2 (pt) 2019-10-01
JP2026062794A (ja) 2026-04-10
US11629146B2 (en) 2023-04-18
DK3548033T3 (da) 2024-07-15
AU2017364901A1 (en) 2019-06-13
JP7495962B2 (ja) 2024-06-05
ES2992063T3 (es) 2024-12-09
AU2023282271A1 (en) 2024-01-18
CA3281817A1 (en) 2026-03-02
CN110337295A (zh) 2019-10-15
CA3045121C (en) 2025-12-16
EP4397308A3 (en) 2024-08-21
PT3548033T (pt) 2024-08-09
HUE068842T2 (hu) 2025-01-28
JP2022141773A (ja) 2022-09-29
US20250163068A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7495962B2 (ja) 化合物及びその使用方法
JP7603118B2 (ja) イオンチャネルモジュレーター
JP7576539B2 (ja) イオンチャネルモジュレーター
US11731966B2 (en) Compounds and their methods of use
US11918571B2 (en) Compounds and their methods of use
US11261188B2 (en) Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) Compounds and their methods of use
WO2018098500A1 (en) Compounds and their methods of use
JP2023503343A (ja) イオンチャネルモジュレーター
HK40013290A (en) Compounds and their methods of use
HK40013290B (en) Compounds and their methods of use
HK40014215A (en) Compounds and their methods of use
EA046723B1 (ru) Соединения и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220712

R150 Certificate of patent or registration of utility model

Ref document number: 7105797

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250